Fujifilm’s Aspire Cristalle breast imaging system violates four patents owned by Hologic, according to the initial ruling on July 26 of U.S. International Trade Commission Judge Clark Cheney.

Women who opt for digital breast tomosynthesis (DBT) over mammography alone are likely to see lower recall rates, improved quality measures and shorter times to biopsy, researchers reported in Academic Radiology this month.

Jeff Immelt, former CEO of General Electric, announced on LinkedIn that he will be advising Collective Health, a start-up that offers software-driven workforce health management systems. The move comes less than a year since he announced his retirement as president and director of GE’s board and less than six months after becoming chairman of Athenahealth.

Toledo, Ohio-based ProMedica announced its acquisition of Quality Care Properties and its principal tenants, HCR ManorCare and Arden Courts. The $4.4 billion transaction was possible thanks to a joint venture with Welltower, an in vestment first focused on healthcare-related real estate.

Alan Andrew Beauchamp, Dallas-based Forest Park Medical Center’s co-founder and former manager, pleaded guilty in a $200 million healthcare fraud case. Beauchamp recruited high-volume specialty doctors and paid them $40 million in bribes and kickbacks to perform surgeries.

This year, the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS) honored numerous technologists with awards for contributions to the fields of nuclear medicine and molecular imaging.

A new study funded by the Harvey L. Neiman Health Policy Institute in Virginia found that dense breast notification policies were associated with an increase in follow-up ultrasound.

GlaxoSmithKline (GSK) announced a four-year, $300 million deal with 23andMe, a personal genomics and biotechnology company based in Mountain View, California. The British pharmaceutical company will have access to genetic information of 23andMe’s five million customers.